We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

QLYS:NASDAQQualys, Inc. Analysis

Data as of 2026-07-14 - not real-time

$164.12

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Qualys (QLYS) is perched at its 52‑week high, trading well above its 20‑day, 50‑day and 200‑day moving averages, with the RSI indicating an overbought condition and a bullish MACD histogram supporting recent momentum. However, the discounted cash‑flow model places the fair value noticeably below the current market price, and the consensus analyst price targets sit well under today’s level, suggesting the stock may be overvalued in the short run.
Fundamentally, the company boasts exceptionally high gross and operating margins, a return on equity that outpaces peers, strong operating and free cash flow, and a net‑cash balance that dwarfs its modest debt load. Recent upgrades from Scotiabank and JPMorgan have added a fresh boost, while the Fear & Greed index signals extreme greed, hinting that market enthusiasm could be overstated. Risk factors include elevated 30‑day volatility and the proximity to a key resistance level, but a low beta and a solid balance sheet temper downside concerns.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI in overbought territory suggesting limited upside
  • Current price hugging the identified resistance level
  • Recent analyst upgrades likely already priced in

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Robust cash generation and high profitability margins
  • Low leverage and net‑cash position providing financial flexibility
  • Growth opportunities in vulnerability management and AI‑driven security services

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Recurring subscription model delivering predictable revenue
  • Strong competitive moat in cloud‑based security platform
  • Continued secular demand for cybersecurity across enterprise and government sectors

Key Metrics & Analysis

Financial Health

Revenue Growth9.80%
Profit Margin29.41%
P/E Ratio29.5
ROE37.72%
ROA13.85%
Debt/Equity9.16
P/B Ratio10.2
Op. Cash Flow$295.1M
Free Cash Flow$237.4M
Industry P/E34.3

Technical Analysis

TrendNeutral
RSI77.1
Support$106.79
Resistance$164.21
MA 20$134.09
MA 50$114.10
MA 200$117.97
MACDBullish
VolumeStable
Fear & Greed Index91.96

Valuation

Fair Value$143.60
Target Price$116.96
Upside/Downside-28.73%
GradeOvervalued
TypeValue

Risk Assessment

Beta0.35
Volatility49.45%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.